GW842166X
GW842166X is a potent and selective CB2 receptor agonist (EC50 = 63 nM) with negligible activity at CB1. It has been investigated in Phase 2 clinical trials and is a valuable research tool for studying CB2 function in inflammatory and neuropathic pain models, both in vitro and in vivo.
Product Specifications
CAS Number
666260-75-9
Product Name Alternative
CB2, CB, Cannabinoid Receptor, CannabinoidReceptor, GW842166X, GW-842166X, Inhibitor, inhibit
Field of Research
Pharmacology & Drug Discovery
Purity
99.47% (May vary between batches)
Solubility
H2O:< 1 mg/mL (insoluble or slightly soluble) ; DMSO:16 mg/mL (35.61 mM) ; Ethanol:< 1 mg/mL (insoluble or slightly soluble)
Smiles
FC (F) (F) c1nc (Nc2cc (Cl) cc (Cl) c2) ncc1C (=O) NCC1CCOCC1
Molecular Formula
C18H17Cl2F3N4O2
Molecular Weight
449.25
Storage Conditions
-20°C
Notes
For research use only.
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
221212-01 50 µL
C19orf10 (C19orf10, Chromosome 19 Open Reading Frame 10, CS010, EUROIMAGE1875335, IL 25, IL 27, IL-25, IL25, IL27, IL27w, Interleukin 25, Interleukin 27 working designation, Interleukin-25, Interleukin25, R33729 1, R337291, SF20, Stromal Cell derived Growth Factor, Stromal Cell derived Growth Factor SF20, Stromal Cell-derived Growth Factor SF20, Uncharacterized Protein C19orf10 Precursor, UPF0556 Protein C19orf10) discontinued
Sign In for Pricing
View Details 221212-02 100 µL
C19orf10 (C19orf10, Chromosome 19 Open Reading Frame 10, CS010, EUROIMAGE1875335, IL 25, IL 27, IL-25, IL25, IL27, IL27w, Interleukin 25, Interleukin 27 working designation, Interleukin-25, Interleukin25, R33729 1, R337291, SF20, Stromal Cell derived Growth Factor, Stromal Cell derived Growth Factor SF20, Stromal Cell-derived Growth Factor SF20, Uncharacterized Protein C19orf10 Precursor, UPF0556 Protein C19orf10) discontinued
Sign In for Pricing
View Details CL3-C52P3-100ug 100 µg
Cynomolgus Claudin-3 Full Length Protein (VLP)
Sign In for Pricing
View Details 